MARKET

PTGX

PTGX

Protagonist
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.68
+0.28
+2.46%
Opening 15:12 10/15 EDT
OPEN
11.49
PREV CLOSE
11.40
HIGH
11.86
LOW
11.19
VOLUME
78.20K
TURNOVER
--
52 WEEK HIGH
16.67
52 WEEK LOW
5.49
MARKET CAP
306.95M
P/E (TTM)
-4.2982
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PTGX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PTGX News

  • The Protagonist Therapeutics (NASDAQ:PTGX) Share Price Is Down 45% So Some Shareholders Are Getting Worried
  • Simply Wall St..10/02 16:39
  • Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting
  • PR Newswire.10/01 12:00
  • Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2
  • PR Newswire.09/25 12:00
  • 80 Biggest Movers From Yesterday
  • Benzinga.09/11 09:11

More

Industry

Biotechnology & Medical Research
+1.95%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Name
Price
%Change

About PTGX

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
More

Webull offers Protagonist Therapeutics Inc (PTGX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.